Traffic Lights - Latest Updates

Last updated: 05/09/2022

Other updates on this site
Drug Name Classification Clinical Indication Comments
TIRZEPATIDE (Mounjaro®) (NEW) Grey Management of overweight and obesity
January 2025: Tirzepatide should NOT be prescribed for managing overweight and obesity. 
Whilst NICE TA1026 was published in December 2024, the ICB awaits further commissioning guidance from NHS England. Further details about local implementation will be provided in due course. Until that time, tirzepatide should not be prescribed for this indication.
GIVINOSTAT (Duvyzat) (NEW) Red For the treatment of Duchenne Muscular Dystrophy.

Via the Early Access Programme only
Gluten Free Products (UPDATED) Do not prescribe

As of February 2025, the prescribing of all gluten free products is ending.
See the ICB website for full details including the consultation process and FAQs.
INSULIN DEGLUDEC/LIRAGLUTIDE (combination product) (Xultophy®) Yellow Diabetes
LEVETIRACETAM Yellow Control of seizures in palliative care medicine

To be used on recommendation from specialist palliative care team only.
Palliative Care Prescribing
LIDOCAINE Patch Do not prescribe All indications except post herpetic neuralgia
LIDOCAINE patch (NEW) Red Sickle cell crisis with focal origin of pain. Managed by haematology only.

Full supply from secondary care, not to be continued in primary care. 
LIDOCAINE patch (NEW) Red Acute use following rib fracture or following thoracic surgery. Short term management only

Full supply from secondary care, not to be continued in primary care. 
LIRAGLUTIDE (Victoza®) Yellow Type 2 diabetes

Dec 2024 update: GLP-1 agonist Victoza to be discontinued | MIMS online

 
MECASERMIN (Increlex®) (NEW) Red For the treatment of growth failure in line with the NHSE Clinical Commissioning Policy.
METHADONE Yellow Palliative care in line with palliative care guidance.

Conditional on recommendation from palliative care team.
Palliative Care Prescribing
NETUPITANT & PALONOSETRON (Akynzeo) (NEW) Red For chemotherapy induced nausea & vomiting.

Feb 2025: Short-term change in practice only whilst there is a supply issue with aprepitant
OCTREOTIDE Yellow Palliative care in line with guidance

Conditional on recommendation from palliative care team.
Palliative Care Prescribing
ONDANSETRON Green Nausea
ONDANSETRON (SC) Yellow For use in palliative care medicine.

Initiation / recommendation via specialist palliative care team only.
Palliative Care Prescribing Guidelines.
PROLONGED RELEASE PREGABALIN (Misabri®) (NEW) Do not prescribe

Not to be used across LLR.
SACUBITRIL and VALSARTAN (Entresto®) Yellow Heart failure

 

 
TADALAFIL (NEW) Red For severe digital ulceration / systemic sclerosis-related Raynaud's phenomenon (SSc-RP)

Restricted to initiation by consultant Rheumatologists
TRANEXAMIC ACID (injection) Yellow To prevent bleeding or treat bleeding in palliative care medicine

To be used on the advice of specialist palliative care team only.
TRANEXAMIC ACID (oral) Green To prevent bleeding or treat bleeding associated with excessive fibrinolysis
URIDINE TRIACETATE (NEW) Red For the treatment of patients exhibiting early-onset severe toxicities following 5-fluorouracil or capecitabine.

Other Updates on this Website

Recent documents from LLR APC and TAS

About the Leicester, Leicestershire and Rutland Area Prescribing Committee

In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more